Lineage Cell Therapeutics Inc (LCTX)

$1.23 +0.01 (0.82%)
Market Cap 278.59M
Revenue (ttm) 9.50M
Net Income (ttm) -18.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -195.89%
Debt to Equity Ratio 0.00
Volume 546,800
Avg Vol 2,285,420
Day's Range N/A - N/A
Shares Out 228.36M
Stochastic %K 53%
Beta 1.66
Analysts Strong Sell
Price Target $4.17

Company Profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the tre...

Industry: Biotechnology
Sector: Healthcare
Phone: 442 287 8990
Address:
2173 Salk Avenue, Suite 200, Carlsbad, United States
Ablidy
Ablidy Sep. 3 at 9:00 PM
$LCTX agree
1 · Reply
Tootie
Tootie Sep. 3 at 8:30 PM
$LCTX This puppy used to sell off at 3:59:59. No mas.
1 · Reply
Logic102
Logic102 Sep. 3 at 6:55 PM
$LCTX Whale watching. They tend to buy big near the close.
1 · Reply
DiligentInvesting
DiligentInvesting Sep. 3 at 6:03 PM
$LCTX Watch volume spike close to the end of the session.
0 · Reply
Logic102
Logic102 Sep. 3 at 4:55 PM
$LCTX Allow me to help translate the link below that Qwertylicious posted. The technology for very early Dry AMD detection and treatment has greatly improved. This opens up the Total Addressable Market for OpRegen significantly. We could well be talking about Prevention before any GA has begun. Don't snooze on this news!!!
2 · Reply
qwertylicious2003
qwertylicious2003 Sep. 3 at 3:00 PM
$LCTX https://www.earlysight.com/wp-content/uploads/2025/09/PR-EarlySight_20250901_final.pdf
2 · Reply
DiligentInvesting
DiligentInvesting Sep. 3 at 1:54 PM
$LCTX
0 · Reply
DiligentInvesting
DiligentInvesting Sep. 3 at 1:43 PM
$LCTX Volume so far: 15,837 ... LOVE IT.
0 · Reply
imatisse
imatisse Sep. 3 at 12:55 PM
The most compelling investment themes are the ones nobody is talking about… yet. ❤️ $LCTX
1 · Reply
Logic102
Logic102 Sep. 3 at 12:44 PM
$LCTX Intelligent investors are overweight Lineage. Short-term, mid-term, long-term winner with a very Bullish chart and multiple catalysts. Cell therapeutics as a whole could well be biotech's version of A I in terms of game-changing breakthroughs.
0 · Reply
Latest News on LCTX
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 1 day ago

Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

Aug 26, 2025, 8:00 AM EDT - 8 days ago

Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 9:16 PM EDT - 22 days ago

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 4:01 PM EDT - 22 days ago

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Aug 5, 2025, 8:00 AM EDT - 4 weeks ago

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Aug 4, 2025, 8:00 AM EDT - 4 weeks ago

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Two Biotech Stocks Poised For Big Moves On Monday

Jun 23, 2025, 7:39 AM EDT - 2 months ago

Two Biotech Stocks Poised For Big Moves On Monday

SANA

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Jun 23, 2025, 7:00 AM EDT - 2 months ago

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

Jun 5, 2025, 8:00 AM EDT - 3 months ago

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 14, 2025, 8:00 AM EDT - 4 months ago

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript

May 13, 2025, 5:53 PM EDT - 4 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:01 PM EDT - 4 months ago

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

May 12, 2025, 8:00 AM EDT - 4 months ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

May 1, 2025, 8:00 AM EDT - 4 months ago

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Apr 22, 2025, 8:00 AM EDT - 4 months ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Apr 21, 2025, 8:00 AM EDT - 4 months ago

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 8:16 PM EDT - 6 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 4:05 PM EDT - 6 months ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Mar 5, 2025, 8:00 AM EST - 6 months ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Feb 11, 2025, 8:00 AM EST - 7 months ago

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

Feb 4, 2025, 8:00 AM EST - 7 months ago

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Jan 27, 2025, 4:05 PM EST - 7 months ago

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Lineage Cell Therapeutics Issues Letter to Stockholders

Jan 6, 2025, 8:00 AM EST - 8 months ago

Lineage Cell Therapeutics Issues Letter to Stockholders

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Nov 21, 2024, 5:00 PM EST - 10 months ago

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Nov 20, 2024, 8:00 AM EST - 10 months ago

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 9:39 PM EST - 10 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024, 4:01 PM EST - 10 months ago

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Nov 7, 2024, 8:00 AM EST - 10 months ago

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

Oct 14, 2024, 8:00 AM EDT - 11 months ago

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Sep 25, 2024, 8:00 AM EDT - 1 year ago

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 12:03 AM EDT - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

Lineage to Present at 2024 BIO International Convention

May 30, 2024, 8:00 AM EDT - 1 year ago

Lineage to Present at 2024 BIO International Convention

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

May 21, 2024, 8:00 AM EDT - 1 year ago

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Call Transcript

May 10, 2024, 12:33 AM EDT - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Call Transcript

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:01 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

May 6, 2024, 8:00 AM EDT - 1 year ago

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

May 2, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Lineage Announces Changes to Board of Directors

Apr 29, 2024, 4:30 PM EDT - 1 year ago

Lineage Announces Changes to Board of Directors

Lineage Announces Appointment of New Board Member

Apr 23, 2024, 8:05 AM EDT - 1 year ago

Lineage Announces Appointment of New Board Member

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

Mar 18, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Mar 13, 2024, 8:00 AM EDT - 1 year ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting

Mar 11, 2024, 8:00 AM EDT - 1 year ago

RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 10:22 PM EST - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript

Ablidy
Ablidy Sep. 3 at 9:00 PM
$LCTX agree
1 · Reply
Tootie
Tootie Sep. 3 at 8:30 PM
$LCTX This puppy used to sell off at 3:59:59. No mas.
1 · Reply
Logic102
Logic102 Sep. 3 at 6:55 PM
$LCTX Whale watching. They tend to buy big near the close.
1 · Reply
DiligentInvesting
DiligentInvesting Sep. 3 at 6:03 PM
$LCTX Watch volume spike close to the end of the session.
0 · Reply
Logic102
Logic102 Sep. 3 at 4:55 PM
$LCTX Allow me to help translate the link below that Qwertylicious posted. The technology for very early Dry AMD detection and treatment has greatly improved. This opens up the Total Addressable Market for OpRegen significantly. We could well be talking about Prevention before any GA has begun. Don't snooze on this news!!!
2 · Reply
qwertylicious2003
qwertylicious2003 Sep. 3 at 3:00 PM
$LCTX https://www.earlysight.com/wp-content/uploads/2025/09/PR-EarlySight_20250901_final.pdf
2 · Reply
DiligentInvesting
DiligentInvesting Sep. 3 at 1:54 PM
$LCTX
0 · Reply
DiligentInvesting
DiligentInvesting Sep. 3 at 1:43 PM
$LCTX Volume so far: 15,837 ... LOVE IT.
0 · Reply
imatisse
imatisse Sep. 3 at 12:55 PM
The most compelling investment themes are the ones nobody is talking about… yet. ❤️ $LCTX
1 · Reply
Logic102
Logic102 Sep. 3 at 12:44 PM
$LCTX Intelligent investors are overweight Lineage. Short-term, mid-term, long-term winner with a very Bullish chart and multiple catalysts. Cell therapeutics as a whole could well be biotech's version of A I in terms of game-changing breakthroughs.
0 · Reply
DiligentInvesting
DiligentInvesting Sep. 3 at 12:31 PM
$LCTX Will break $1.31 today.
1 · Reply
alphadog10
alphadog10 Sep. 3 at 12:18 PM
$LCTX $20.
1 · Reply
alphadog10
alphadog10 Sep. 3 at 12:17 PM
$LCTX Im never selling this stock. I will only add on drops
0 · Reply
MR_PINKS
MR_PINKS Sep. 3 at 12:15 PM
$LCTX Punishing Markets by year end....LCTX will weather the storm....
1 · Reply
Invest2live
Invest2live Sep. 3 at 3:57 AM
$GOSS 178% already. Congrats 🎈🎉🌿 Checkout $ASRT and $LCTX
1 · Reply
CMAC1211
CMAC1211 Sep. 2 at 9:26 PM
$LCTX - 2nd highest trade volume day over the past month plus
0 · Reply
alphadog10
alphadog10 Sep. 2 at 9:23 PM
$LCTX do these shipments create shareholder value ?
1 · Reply
alphadog10
alphadog10 Sep. 2 at 9:21 PM
$LCTX new here. whats the significance of tracking shipments of cells? Arent cells supposed to come over and be used in trials. Are we supposed to be happy ? Thanks.
0 · Reply
Pot_of_Greed
Pot_of_Greed Sep. 2 at 9:15 PM
$LCTX I’m expecting a big week with all the hopium we got going on!
2 · Reply
Logic102
Logic102 Sep. 2 at 8:58 PM
$LCTX I was thinking that a Manufacturing deal would beat a Phase 3 announcement. Now, with George's find, I'm not so sure. Oh my, you want to be in this stock heavily right now. Near term catalysts are within sight, certainly one of these major ones hits before year's end.
2 · Reply
qwertylicious2003
qwertylicious2003 Sep. 2 at 8:32 PM
$LCTX bought more!
0 · Reply
qwertylicious2003
qwertylicious2003 Sep. 2 at 8:27 PM
$LCTX Another HUGE part of the import story... that large 236 piece RPE shipment? Not labeled OpRegen... Why? My guess is this was the large bank of sample tissue for other testing, including manufacturing comparability. We must be getting close.... oh so close!
1 · Reply